Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AP 12009 vs standard chemotherapy in recurrent or refractory anaplastic astrocytoma or secondary glioblastoma
2007-005802-38Phase 3Terminated
- Sponsor
- Antisense Pharma
- Start
- Jun 2008
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of trabedersen in anaplastic astrocytoma (AA), glioblastoma (GBM), sponsored by Antisense Pharma. Started Jun 2008; status: terminated.
02
Drugs
trabedersen
03
Conditions
anaplastic astrocytoma (AA)glioblastoma (GBM)
Beyond the preview
Go deeper on 2007-005802-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-005802-38.